Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

英文中文

Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes 成年亚洲印度2型糖尿病患者代谢功能障碍相关脂肪变性肝病诊断和治疗的共识指南

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103209

Anoop Misra , Ashish Kumar , Mohammad Shafi Kuchay , Amerta Ghosh , Seema Gulati , Narendra Singh Choudhary , Deep Dutta , Praveen Sharma , Naval K. Vikram

引用次数: 0

Maternal serum folate status during early pregnancy: Sex-specific association with neonatal adiposity 妊娠早期母体血清叶酸状态：与新生儿肥胖的性别特异性关联

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103222

Nishanthi Periyathambi , Nithya Sukumar , Yonas Ghebremichael-Weldeselassie , Antonysunil Adaikalakoteswari , Chittaranjan Yajnik , Caroline Fall , Ponnusamy Saravanan

Background & aims

Early pregnancy folate has been associated with GDM and possible adiposity in the newborn. The present study examined associations between maternal early pregnancy folate levels and sex-specific neonatal anthropometry. We further explored possible mediation by maternal glycemia on the association between folate and neonatal adiposity.

Methods

Sub-group data (n = 511) from a UK multi-ethnic early pregnancy longitudinal study (micronutrients in Pregnancy as a Risk factor for gestational Diabetes and Effects on mother and baby; PRiDE) was used. Maternal serum folate was assessed during early pregnancy (Mean ± SD = 12.5 ± 1.6 gestational weeks) and infant anthropometry including skinfold thickness (SFT) and mid-upper arm circumference (MUAC) at birth. Multiple linear regression was performed to analyse the relationship between maternal folate and infant adiposity indices. Interaction analysis was used to identify maternal glucose mediation of this relationship.

Results

Excess folate levels (≥45 nmol/l) were found in 40.3 % pregnant women (n = 206). Early pregnancy folate (1 SD unit) was positively associated with male newborn triceps SFT (std β = 0.17 (95 % CI: 0.06, 0.29; p < 0.05)) after adjusting for key maternal and infant confounders in multiple comparisons using Benjamini-Hochberg procedure. However, no associations were seen in female newborns. No influence of maternal fasting (FPG) and 2-h plasma glucose (2 h-PG) were detected on the association between folate and newborn anthropometry.

Conclusion

Our findings suggest a potential sex-specific influence of maternal folate on infant anthropometric indices. The association between early pregnancy folate on newborn adiposity was not mediated by maternal FPG and/or 2 h-PG at 24–28 weeks.

背景,目的妊娠早期叶酸与GDM和新生儿可能的肥胖有关。本研究调查了孕妇妊娠早期叶酸水平与新生儿性别特异性人体测量之间的关系。我们进一步探讨了母体血糖在叶酸和新生儿肥胖之间可能的中介作用。方法：来自英国多民族妊娠早期纵向研究的亚组数据（n = 511）(孕期微量营养素作为妊娠期糖尿病的危险因素及其对母婴的影响；骄傲)被使用。在妊娠早期（Mean±SD = 12.5±1.6孕周）评估孕妇血清叶酸，并在婴儿出生时进行人体测量，包括皮褶厚度（SFT）和中上臂围（MUAC）。采用多元线性回归分析母体叶酸与婴儿肥胖指数之间的关系。相互作用分析用于确定母体葡萄糖介导这种关系。结果40.3%（206例）孕妇叶酸水平≥45 nmol/l。妊娠早期叶酸（1 SD单位）与男婴三头肌SFT呈正相关(std β = 0.17 (95% CI: 0.06, 0.29；p & lt;0.05))，在使用Benjamini-Hochberg程序调整多重比较中的关键母婴混杂因素后。然而，在女性新生儿中没有发现关联。母体空腹（FPG）和2小时血浆葡萄糖（2 h-PG）未检测到叶酸与新生儿人体测量的关系。结论母体叶酸对婴儿人体测量指标有潜在的性别特异性影响。孕早期叶酸与新生儿肥胖之间的关系不受母体FPG和/或24-28周时2 h-PG的介导。

{"title":"Maternal serum folate status during early pregnancy: Sex-specific association with neonatal adiposity","authors":"Nishanthi Periyathambi , Nithya Sukumar , Yonas Ghebremichael-Weldeselassie , Antonysunil Adaikalakoteswari , Chittaranjan Yajnik , Caroline Fall , Ponnusamy Saravanan","doi":"10.1016/j.dsx.2025.103222","DOIUrl":"10.1016/j.dsx.2025.103222","url":null,"abstract":"<div><h3>Background & aims</h3><div>Early pregnancy folate has been associated with GDM and possible adiposity in the newborn. The present study examined associations between maternal early pregnancy folate levels and sex-specific neonatal anthropometry. We further explored possible mediation by maternal glycemia on the association between folate and neonatal adiposity.</div></div><div><h3>Methods</h3><div>Sub-group data (<em>n</em> = 511) from a UK multi-ethnic early pregnancy longitudinal study (micronutrients in Pregnancy as a Risk factor for gestational Diabetes and Effects on mother and baby; PRiDE) was used. Maternal serum folate was assessed during early pregnancy (Mean ± SD = 12.5 ± 1.6 gestational weeks) and infant anthropometry including skinfold thickness (SFT) and mid-upper arm circumference (MUAC) at birth. Multiple linear regression was performed to analyse the relationship between maternal folate and infant adiposity indices. Interaction analysis was used to identify maternal glucose mediation of this relationship.</div></div><div><h3>Results</h3><div>Excess folate levels (≥45 nmol/l) were found in 40.3 % pregnant women (<em>n</em> = 206). Early pregnancy folate (1 SD unit) was positively associated with male newborn triceps SFT (std β = 0.17 (95 % CI: 0.06, 0.29; <em>p <</em> 0.05)) after adjusting for key maternal and infant confounders in multiple comparisons using Benjamini-Hochberg procedure. However, no associations were seen in female newborns. No influence of maternal fasting (FPG) and 2-h plasma glucose (2 h-PG) were detected on the association between folate and newborn anthropometry.</div></div><div><h3>Conclusion</h3><div>Our findings suggest a potential sex-specific influence of maternal folate on infant anthropometric indices. The association between early pregnancy folate on newborn adiposity was not mediated by maternal FPG and/or 2 h-PG at 24–28 weeks.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103222"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials 西马鲁肽2.4 mg和替西帕肽5-15 mg治疗伴有或不伴有2型糖尿病的肥胖的比较疗效和安全性：一项3期临床试验的系统综述

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103212

Akriti Singh , Awadhesh Kumar Singh , Ritu Singh , Anoop Misra

Background and aims

Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of both these agents in people with obesity/overweight with or without type 2 diabetes (T2D). We systematically reviewed Phase 3 randomized controlled trials (RCTs) conducted with two agents to synthesize the comparative efficacy and safety outcomes.

Methods

We systematically searched PubMed electronic databases until December 15, 2024, using selected keywords and Boolean “AND.” Subsequently, we compared the most closely matched trials conducted with semaglutide 2.4 mg and tirzepatide through an adjusted (if baseline imbalance in treatment outcome modifiers present) or unadjusted (in the absence of baseline imbalance) indirect treatment comparison method.

Results

We identified one trial each of semaglutide 2.4 mg (STEP-1) and tirzepatide 5, 10, and 15 mg (SURMOUNT-1) in obese or overweight people without T2D and one trial each of semaglutide 2.4 mg (STEP-2) and tirzepatide 10 and 15 mg (SURMOUNT-2) in overweight people with T2D that were almost entirely comparable concerning baseline outcome modifier characteristics. Our unadjusted analysis without individual patients' data found relatively higher (4 and 5.4 % additional) weight loss, HbA1c (−0.4 % additional) reduction, and fewer gastrointestinal side effects (GI S/E) with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg, in the intention-to-treat analysis.

Conclusion

Tirzepatide 10 and 15 mg are more effective and have fewer GI S/E than semaglutide 2.4 mg. A well-powered head-to-head RCT is currently needed to confirm these findings.

背景和目的：西马鲁肽2.4 mg和替西帕肽最近都被批准用于肥胖症的慢性治疗。目前缺乏文献比较这两种药物对伴有或不伴有2型糖尿病（T2D）的肥胖/超重患者的疗效和安全性。我们系统地回顾了两种药物进行的3期随机对照试验（rct），以综合比较疗效和安全性结果。方法系统检索PubMed电子数据库，检索时间截止到2024年12月15日。随后，我们通过调整（如果治疗结果调节因子存在基线不平衡）或未调整（在没有基线不平衡的情况下）间接治疗比较方法，比较了使用semaglutide 2.4 mg和tizepatide进行的最密切匹配的试验。结果：我们确定了在肥胖或超重无T2D患者中分别使用塞马鲁肽2.4 mg （STEP-1）和替西肽5、10和15 mg （SURMOUNT-1）的一项试验，以及在超重合并T2D患者中分别使用塞马鲁肽2.4 mg （STEP-2）和替西肽10和15 mg （SURMOUNT-2）的一项试验，这些试验在基线结局调节因子特征上几乎完全可比较。在意向治疗分析中，我们在没有个体患者数据的未经调整分析中发现，与西马鲁肽2.4 mg相比，替西帕肽10和15 mg的体重减轻相对较高（增加4%和5.4%），HbA1c降低（增加- 0.4%），胃肠道副作用（GI S/E）更少。结论替西帕肽10和15 mg比西马鲁肽2.4 mg更有效，GI S/E更低。目前需要一项强有力的头对头随机对照试验来证实这些发现。

{"title":"Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5–15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials","authors":"Akriti Singh , Awadhesh Kumar Singh , Ritu Singh , Anoop Misra","doi":"10.1016/j.dsx.2025.103212","DOIUrl":"10.1016/j.dsx.2025.103212","url":null,"abstract":"<div><h3>Background and aims</h3><div>Both semaglutide 2.4 mg and tirzepatide have been recently approved for chronic use in obesity. There is a lack of literature comparing the efficacy and safety of both these agents in people with obesity/overweight with or without type 2 diabetes (T2D). We systematically reviewed Phase 3 randomized controlled trials (RCTs) conducted with two agents to synthesize the comparative efficacy and safety outcomes.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed electronic databases until December 15, 2024, using selected keywords and Boolean “AND.” Subsequently, we compared the most closely matched trials conducted with semaglutide 2.4 mg and tirzepatide through an adjusted (if baseline imbalance in treatment outcome modifiers present) or unadjusted (in the absence of baseline imbalance) indirect treatment comparison method.</div></div><div><h3>Results</h3><div>We identified one trial each of semaglutide 2.4 mg (STEP-1) and tirzepatide 5, 10, and 15 mg (SURMOUNT-1) in obese or overweight people without T2D and one trial each of semaglutide 2.4 mg (STEP-2) and tirzepatide 10 and 15 mg (SURMOUNT-2) in overweight people with T2D that were almost entirely comparable concerning baseline outcome modifier characteristics. Our unadjusted analysis without individual patients' data found relatively higher (4 and 5.4 % additional) weight loss, HbA1c (−0.4 % additional) reduction, and fewer gastrointestinal side effects (GI S/E) with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg, in the intention-to-treat analysis.</div></div><div><h3>Conclusion</h3><div>Tirzepatide 10 and 15 mg are more effective and have fewer GI S/E than semaglutide 2.4 mg. A well-powered head-to-head RCT is currently needed to confirm these findings.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103212"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we best support insulin self-titration in type 2 diabetes patients: A systematic review and network meta-analysis 我们如何才能最好地支持2型糖尿病患者的胰岛素自我滴定：一项系统综述和网络荟萃分析

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103221

Panitan Pitak , Kansak Boonpattharatthiti , Anjana Fuangchan , Ines Krass , Teerapon Dhippayom

Introduction

The efficacy of insulin self-titration in type 2 diabetes (T2D) varies by support strategy. This study aimed to identify the effects of different insulin self-titration support strategies in patients with T2D.

Methods

PubMed, EMBASE, CENTRAL, and EBSCO Open Dissertations were searched from inception to January 2023. Randomized controlled trials (RCTs) on T2D patients that reported HbA1c reduction of insulin self-titration supports were included. The interventions were classified based on the following components: dosage guidance (DG), non-dosage guidance (NDG) and empowerment. The pooled estimates were presented as mean differences (MDs) and risk ratios (RRs) with 95 % confidence interval (CI) using a random-effects model. The certainty of evidence was evaluated utilizing the CINeMA online platform.

Results

Seventeen RCTs (13,528 participants) were included. Compared with usual care (UC), the greatest reduction in HbA1c was observed in patients receiving dosage guidance/Empowerment (MD −1.20; 95 %CI: −2.33,−0.07), with moderate certainty of evidence. Lesser HbA1c reduction, MD [95 % CI], were observed in other support strategies when compared with usual care as follows: −0.97 [−1.24,−0.69] in non-dosage guidance/Empowerment, −0.42 [−0.60,−0.24] in dosage guidance, and −0.31 [−0.58,−0.03] in non-dosage guidance. The risk of severe hypoglycemia was not significantly difference among all support strategies, with very low certainty.

Conclusions

Incorporating patient empowerment into insulin self-titration support strategy, either dosage or non-dosage guidance, is more effective in lowering HbA1c.

胰岛素自我滴定治疗2型糖尿病（T2D）的疗效因支持策略而异。本研究旨在确定不同胰岛素自我滴定支持策略对t2dm患者的影响。方法检索spubmed、EMBASE、CENTRAL和EBSCO自建校至2023年1月的开放论文。随机对照试验（RCTs）中t2dm患者报告HbA1c降低胰岛素自我滴定支持。干预措施按剂量指导（DG）、非剂量指导（NDG）和授权（empowerment）三部分进行分类。使用随机效应模型，汇总估计以95%置信区间（CI）的平均差异（md）和风险比（rr）表示。利用CINeMA在线平台评估证据的确定性。结果纳入17项随机对照试验（rct），共13528名受试者。与常规护理（UC）相比，接受剂量指导/授权的患者HbA1c降低幅度最大(MD - 1.20；95% CI:−2.33,−0.07)，证据确定性中等。与常规护理相比，其他支持策略的HbA1c降低幅度较小，MD [95% CI]如下：非剂量指导/赋权组为- 0.97[- 1.24,- 0.69]，剂量指导组为- 0.42[- 0.60,- 0.24]，非剂量指导组为- 0.31[- 0.58,- 0.03]。严重低血糖的风险在各支持策略间无显著差异，确定性极低。结论将患者授权纳入胰岛素自我滴定支持策略，无论是剂量指导还是非剂量指导，都能更有效地降低HbA1c。

{"title":"How can we best support insulin self-titration in type 2 diabetes patients: A systematic review and network meta-analysis","authors":"Panitan Pitak , Kansak Boonpattharatthiti , Anjana Fuangchan , Ines Krass , Teerapon Dhippayom","doi":"10.1016/j.dsx.2025.103221","DOIUrl":"10.1016/j.dsx.2025.103221","url":null,"abstract":"<div><h3>Introduction</h3><div>The efficacy of insulin self-titration in type 2 diabetes (T2D) varies by support strategy. This study aimed to identify the effects of different insulin self-titration support strategies in patients with T2D.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, CENTRAL, and EBSCO Open Dissertations were searched from inception to January 2023. Randomized controlled trials (RCTs) on T2D patients that reported HbA1c reduction of insulin self-titration supports were included. The interventions were classified based on the following components: dosage guidance (DG), non-dosage guidance (NDG) and empowerment. The pooled estimates were presented as mean differences (MDs) and risk ratios (RRs) with 95 % confidence interval (CI) using a random-effects model. The certainty of evidence was evaluated utilizing the CINeMA online platform.</div></div><div><h3>Results</h3><div>Seventeen RCTs (13,528 participants) were included. Compared with usual care (UC), the greatest reduction in HbA1c was observed in patients receiving dosage guidance/Empowerment (MD −1.20; 95 %CI: −2.33,−0.07), with moderate certainty of evidence. Lesser HbA1c reduction, MD [95 % CI], were observed in other support strategies when compared with usual care as follows: −0.97 [−1.24,−0.69] in non-dosage guidance/Empowerment, −0.42 [−0.60,−0.24] in dosage guidance, and −0.31 [−0.58,−0.03] in non-dosage guidance. The risk of severe hypoglycemia was not significantly difference among all support strategies, with very low certainty.</div></div><div><h3>Conclusions</h3><div>Incorporating patient empowerment into insulin self-titration support strategy, either dosage or non-dosage guidance, is more effective in lowering HbA1c.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103221"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) in the treatment of diabetic neuropathy: A systematic review and meta-analysis of randomized controlled trials 频率节律性电调制系统（FREMS）治疗糖尿病神经病变的疗效：随机对照试验的系统回顾和荟萃分析

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103223

Alireza Azarboo , Parisa Fallahtafti , Amin Javidan , Negar Zareshahi , Hossein Souri Giglou , Shabboo Moayyed , Amirhossein Ghaseminejad-Raeini , Mahboobeh Hemmatabadi

Background

Painful diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes with limited treatment options. Frequency Rhythmic Electrical Modulated System (FREMS), a non-invasive electrotherapy, has shown promise in symptom management.

Methods

Databases, including PubMed, Scopus, and Embase were searched until October 2024. Randomized controlled trials (RCTs) involving adults with DPN comparing FREMS with control were included. Data on Visual Analog Scale (VAS) scores and nerve conduction were extracted. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed using RoB 2. Heterogeneity was quantified via I² statistics, with sensitivity analyses and publication bias evaluation.

Results

Five RCTs (333 participants) were included. Meta-analysis indicated that FREMS significantly reduced daytime VAS pain scores post-treatment (SMD -0.56, 95 % CI -0.82 to −0.29, I² = 4 %) and at follow-up (SMD -0.47, 95 % CI -0.73 to −0.21, I² = 0 %). Night-time VAS pain scores also improved post-treatment (SMD -0.54, 95 % CI -0.80 to −0.27, I² = 44 %) and at follow-up (SMD -0.38, 95 % CI -0.65 to −0.12, I² = 1 %). FREMS improved motor nerve conduction but showed no effect on sensory conduction or microvascular blood flow.

Conclusion

FREMS effectively reduces DPN pain with sustained benefits and a favorable safety profile. Further research should standardize treatment protocols and assess long-term outcomes for clinical integration.

疼痛性糖尿病周围神经病变（DPN）是糖尿病的一种衰弱性并发症，治疗选择有限。频率节律电调制系统（FREMS）是一种非侵入性电疗，在症状治疗中显示出前景。方法检索PubMed、Scopus、Embase等数据库至2024年10月。纳入随机对照试验（RCTs），将成年DPN患者的FREMS与对照组进行比较。提取视觉模拟评分（VAS）和神经传导数据。95%置信区间（ci）的标准化平均差异（SMDs）使用随机效应模型进行汇总。偏倚风险采用RoB 2进行评估。异质性通过I2统计量化，并进行敏感性分析和发表偏倚评价。结果共纳入5项随机对照试验（rct），共333名受试者。meta分析显示，FREMS显著降低了治疗后（SMD -0.56, 95% CI -0.82至- 0.29,I2 = 4%）和随访时（SMD -0.47, 95% CI -0.73至- 0.21,I2 = 0%）的日间VAS疼痛评分。夜间VAS疼痛评分在治疗后（SMD -0.54, 95% CI -0.80至- 0.27,I2 = 44%）和随访时（SMD -0.38, 95% CI -0.65至- 0.12,I2 = 1%）也有所改善。FREMS改善运动神经传导，但对感觉传导和微血管血流无影响。结论frems可有效减轻DPN疼痛，具有持续的疗效和良好的安全性。进一步的研究应使治疗方案标准化，并评估临床整合的长期结果。

{"title":"Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) in the treatment of diabetic neuropathy: A systematic review and meta-analysis of randomized controlled trials","authors":"Alireza Azarboo , Parisa Fallahtafti , Amin Javidan , Negar Zareshahi , Hossein Souri Giglou , Shabboo Moayyed , Amirhossein Ghaseminejad-Raeini , Mahboobeh Hemmatabadi","doi":"10.1016/j.dsx.2025.103223","DOIUrl":"10.1016/j.dsx.2025.103223","url":null,"abstract":"<div><h3>Background</h3><div>Painful diabetic peripheral neuropathy (DPN) is a debilitating complication of diabetes with limited treatment options. Frequency Rhythmic Electrical Modulated System (FREMS), a non-invasive electrotherapy, has shown promise in symptom management.</div></div><div><h3>Methods</h3><div>Databases, including PubMed, Scopus, and Embase were searched until October 2024. Randomized controlled trials (RCTs) involving adults with DPN comparing FREMS with control were included. Data on Visual Analog Scale (VAS) scores and nerve conduction were extracted. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were pooled using random-effects models. Risk of bias was assessed using RoB 2. Heterogeneity was quantified via I<sup>2</sup> statistics, with sensitivity analyses and publication bias evaluation.</div></div><div><h3>Results</h3><div>Five RCTs (333 participants) were included. Meta-analysis indicated that FREMS significantly reduced daytime VAS pain scores post-treatment (SMD -0.56, 95 % CI -0.82 to −0.29, I<sup>2</sup> = 4 %) and at follow-up (SMD -0.47, 95 % CI -0.73 to −0.21, I<sup>2</sup> = 0 %). Night-time VAS pain scores also improved post-treatment (SMD -0.54, 95 % CI -0.80 to −0.27, I<sup>2</sup> = 44 %) and at follow-up (SMD -0.38, 95 % CI -0.65 to −0.12, I<sup>2</sup> = 1 %). FREMS improved motor nerve conduction but showed no effect on sensory conduction or microvascular blood flow.</div></div><div><h3>Conclusion</h3><div>FREMS effectively reduces DPN pain with sustained benefits and a favorable safety profile. Further research should standardize treatment protocols and assess long-term outcomes for clinical integration.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 3","pages":"Article 103223"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor regarding “The impact of food-based dietary strategies on achieving type 2 diabetes remission: A systematic review” 关于“以食物为基础的饮食策略对实现2型糖尿病缓解的影响：系统综述”的致编辑的信

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103188

Irfat Islam Eva , Priyadarshini Deb , Muhammad Ali Muzammil

引用次数: 0

Response to the Letter to the Editor regarding “The impact of food-based dietary strategies on achieving type 2 diabetes remission: A systematic review” 关于“以食物为基础的饮食策略对实现2型糖尿病缓解的影响：一项系统综述”的致编辑信的回复

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103189

Hadis Mozaffari , Annalijn I. Conklin

引用次数: 0

Diabetes care in Gaza: A call to action for providing healthcare amid conflict 加沙的糖尿病护理：在冲突中提供医疗保健的行动呼吁

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-03-01 DOI: 10.1016/j.dsx.2025.103210

Sumarno Adi Subrata

引用次数: 0

Impact of type 1 diabetes mellitus on mortality rate and outcome of hospitalized patients with myocardial infarction 1型糖尿病对住院心肌梗死患者死亡率及转归的影响

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103201

Volker H. Schmitt , Lukas Hobohm , Omar Hahad , Visvakanth Sivanathan , Frank P. Schmidt , Thomas Münzel , Philipp Lurz , Tommaso Gori , Karsten Keller

Introduction

Type 1 diabetes mellitus (T1D) is associated with an increased cardiovascular risk. We aimed to investigate the influence of T1D on myocardial infarction (MI) patients’ mortality.

Materials and methods

The German nationwide inpatient sample 2005–2016 was used for statistical analysis. Hospitalized MI patients were stratified for T1D and impact of T1D on in-hospital outcomes was investigated.

Results

In total, 3,307,703 hospitalizations of MI patients (37.6 % females, 56.8 % aged ≥70 years) were counted in Germany 2005–2016 and included in this analysis. In 18,625 (0.6 %) of the cases additionally T1D was coded. Overall, 410,737 (12.4 %) in-hospital deaths occurred within the investigation period. MI patients with T1D were younger (64.0 [IQR 52.0–75.0] vs. 73.0 [62.0–81.0] years, P < 0.001), more often female (38.7 % vs. 37.6 %, P < 0.001) and obese (13.2 % vs. 9.3 %, P < 0.001). Comorbidities like peripheral arterial (14.2 % vs. 6.4 %, P < 0.001) and kidney disease (38.5 % vs. 27.2 %, P < 0.001) were more prevalent in MI patients with T1D. T1D was an independent risk factor for in-hospital death (OR 1.23 [95%CI 1.18–1.29], P < 0.001), recurrent MI (OR 1.56 [95%CI 1.35–1.80], P < 0.001), and stroke (OR 1.75 [95%CI 1.63–1.88], P < 0.001). While percutaneous coronary intervention (PCI, 37.8 % vs. 42.0 %, P < 0.001) was less often, coronary artery bypass grafting (CABG, 7.4 % vs. 4.6 %, P < 0.001) was more often performed in MI patients with T1D, confirmed by regression analysis (PCI: OR 0.66 [95%CI 0.64–0.68], P < 0.001; CABG: OR 1.54 [95%CI 1.45–1.63], P < 0.001).

Conclusions

T1D represents an important and independent risk factor for mortality in MI patients. The results emphasize the high vulnerability of T1D patients who suffer from MI.

简介1型糖尿病（T1D）与心血管风险增加有关。我们旨在研究 T1D 对心肌梗死（MI）患者死亡率的影响：采用 2005-2016 年德国全国住院病人样本进行统计分析。对住院心肌梗死患者进行T1D分层，并调查T1D对住院结果的影响：2005-2016年，德国共统计了3,307,703名住院心肌梗死患者（37.6%为女性，56.8%年龄≥70岁），并将其纳入本次分析。其中18625例（0.6%）的病例被额外编码为T1D。在调查期内，共有410737人（12.4%）在院内死亡。患有 T1D 的心肌梗死患者更年轻（64.0 [IQR 52.0-75.0] 岁 vs. 73.0 [62.0-81.0] 岁，P 结论：T1D 是心肌梗死的重要独立危险因素：T1D 是导致心肌梗死患者死亡的一个重要且独立的风险因素。研究结果表明，T1D 患者极易罹患心肌梗死。

{"title":"Impact of type 1 diabetes mellitus on mortality rate and outcome of hospitalized patients with myocardial infarction","authors":"Volker H. Schmitt , Lukas Hobohm , Omar Hahad , Visvakanth Sivanathan , Frank P. Schmidt , Thomas Münzel , Philipp Lurz , Tommaso Gori , Karsten Keller","doi":"10.1016/j.dsx.2025.103201","DOIUrl":"10.1016/j.dsx.2025.103201","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 1 diabetes mellitus (T1D) is associated with an increased cardiovascular risk. We aimed to investigate the influence of T1D on myocardial infarction (MI) patients’ mortality.</div></div><div><h3>Materials and methods</h3><div>The German nationwide inpatient sample 2005–2016 was used for statistical analysis. Hospitalized MI patients were stratified for T1D and impact of T1D on in-hospital outcomes was investigated.</div></div><div><h3>Results</h3><div>In total, 3,307,703 hospitalizations of MI patients (37.6 % females, 56.8 % aged ≥70 years) were counted in Germany 2005–2016 and included in this analysis. In 18,625 (0.6 %) of the cases additionally T1D was coded. Overall, 410,737 (12.4 %) in-hospital deaths occurred within the investigation period. MI patients with T1D were younger (64.0 [IQR 52.0–75.0] vs. 73.0 [62.0–81.0] years, P < 0.001), more often female (38.7 % vs. 37.6 %, P < 0.001) and obese (13.2 % vs. 9.3 %, P < 0.001). Comorbidities like peripheral arterial (14.2 % vs. 6.4 %, P < 0.001) and kidney disease (38.5 % vs. 27.2 %, P < 0.001) were more prevalent in MI patients with T1D. T1D was an independent risk factor for in-hospital death (OR 1.23 [95%CI 1.18–1.29], P < 0.001), recurrent MI (OR 1.56 [95%CI 1.35–1.80], P < 0.001), and stroke (OR 1.75 [95%CI 1.63–1.88], P < 0.001). While percutaneous coronary intervention (PCI, 37.8 % vs. 42.0 %, P < 0.001) was less often, coronary artery bypass grafting (CABG, 7.4 % vs. 4.6 %, P < 0.001) was more often performed in MI patients with T1D, confirmed by regression analysis (PCI: OR 0.66 [95%CI 0.64–0.68], P < 0.001; CABG: OR 1.54 [95%CI 1.45–1.63], P < 0.001).</div></div><div><h3>Conclusions</h3><div>T1D represents an important and independent risk factor for mortality in MI patients. The results emphasize the high vulnerability of T1D patients who suffer from MI.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"19 2","pages":"Article 103201"},"PeriodicalIF":4.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of the current issue 当前问题的重点

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2025-02-01 DOI: 10.1016/j.dsx.2025.103211

Ningjian Wang (Associate Editor) , Anoop Misra (Editor-in-Chief)

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀